VF
MLYS icon

Virtu Financial’s Mineralys Therapeutics MLYS Stock Holding History

Virtu Financial’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,203
Closed -$400K – 1814
2025
Q1 		$400K Buy
+25,203
New +$290K 0.02% 569

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Virtu Financial's MLYS Position: Q2 2025 in Review

Virtu Financial sold out of Mineralys Therapeutics (MLYS) in Q2 2025, closing a stake of 25,203 shares — an estimated $400K sold.

Virtu Financial first reported a position in MLYS in Q1 2025 and held it in 1 quarter. The position peaked at $400K in Q1 2025. 165 funds tracked by Wall St. Rank hold MLYS as of Q2 2025.

  • Virtu Financial reported no remaining Mineralys Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Virtu Financial sold 25,203 Mineralys Therapeutics shares in Q2 2025, an estimated $400K.
  • Virtu Financial first reported a position in Mineralys Therapeutics in Q1 2025 and held it in 1 quarter.
  • Virtu Financial's Mineralys Therapeutics position peaked at $400K in Q1 2025.
  • 165 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2025.

Based on Virtu Financial's 13F filing for Q2 2025, filed 12 Aug 2025.